A detailed history of Cullen/Frost Bankers, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 30,422 shares of BMY stock, worth $1.79 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
30,422
Previous 38,956 21.91%
Holding current value
$1.79 Million
Previous $1.62 Million 2.66%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$39.66 - $51.75 $338,458 - $441,634
-8,534 Reduced 21.91%
30,422 $1.57 Million
Q2 2024

Aug 05, 2024

SELL
$40.25 - $52.99 $5.04 Million - $6.63 Million
-125,153 Reduced 76.26%
38,956 $1.62 Million
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $5.59 Million - $6.34 Million
-116,578 Reduced 41.53%
164,109 $8.9 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $1.95 Million - $2.33 Million
-40,307 Reduced 12.56%
280,687 $14.4 Million
Q3 2023

Nov 02, 2023

SELL
$57.89 - $64.73 $325,110 - $363,523
-5,616 Reduced 1.72%
320,994 $18.6 Million
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $265,415 - $294,702
-4,166 Reduced 1.26%
326,610 $20.9 Million
Q1 2023

May 05, 2023

SELL
$65.71 - $74.53 $264,548 - $300,057
-4,026 Reduced 1.2%
330,776 $22.9 Million
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $3.71 Million - $4.39 Million
54,151 Added 19.29%
334,802 $24.1 Million
Q3 2022

Nov 07, 2022

BUY
$0.13 - $76.84 $1,980 - $1.17 Million
15,235 Added 5.74%
280,651 $20 Million
Q2 2022

Aug 05, 2022

BUY
$72.62 - $79.98 $746,606 - $822,274
10,281 Added 4.03%
265,416 $20.5 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $808,523 - $969,491
13,151 Added 5.43%
255,135 $18.7 Million
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $224,227 - $261,396
4,181 Added 1.76%
241,984 $15.1 Million
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $298,749 - $349,946
5,049 Added 2.17%
237,803 $14.1 Million
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $173,967 - $189,450
2,810 Added 1.22%
232,754 $15.6 Million
Q1 2021

May 05, 2021

BUY
$59.34 - $66.74 $42,962 - $48,319
724 Added 0.32%
229,944 $14.5 Million
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $300,536 - $340,563
-5,205 Reduced 2.22%
229,220 $14.2 Million
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $388,054 - $430,015
-6,757 Reduced 2.8%
234,425 $14.1 Million
Q2 2020

Aug 05, 2020

BUY
$54.82 - $64.09 $591,836 - $691,915
10,796 Added 4.69%
241,182 $14.2 Million
Q1 2020

May 01, 2020

BUY
$46.4 - $67.43 $324,057 - $470,931
6,984 Added 3.13%
230,386 $12.8 Million
Q4 2019

Feb 06, 2020

BUY
$49.21 - $64.19 $6.08 Million - $7.93 Million
123,552 Added 123.74%
223,402 $14.3 Million
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $359,524 - $426,268
8,406 Added 9.19%
99,850 $5.06 Million
Q2 2019

Aug 01, 2019

BUY
$44.62 - $49.34 $254,824 - $281,780
5,711 Added 6.66%
91,444 $4.15 Million
Q1 2019

Apr 30, 2019

SELL
$45.12 - $53.8 $145,918 - $173,989
-3,234 Reduced 3.64%
85,733 $4.09 Million
Q4 2018

Feb 06, 2019

SELL
$48.76 - $63.23 $433,622 - $562,304
-8,893 Reduced 9.09%
88,967 $4.63 Million
Q3 2018

Oct 29, 2018

SELL
$55.19 - $62.25 $1.67 Million - $1.88 Million
-30,261 Reduced 23.62%
97,860 $6.08 Million
Q2 2018

Jul 27, 2018

SELL
$50.53 - $62.98 $2.51 Million - $3.13 Million
-49,686 Reduced 27.94%
128,121 $7.09 Million
Q1 2018

May 11, 2018

SELL
$59.92 - $68.98 $1.82 Million - $2.09 Million
-30,344 Reduced 14.58%
177,807 $11.2 Million
Q4 2017

Jan 31, 2018

SELL
$59.94 - $65.35 $504,275 - $549,789
-8,413 Reduced 3.88%
208,151 $12.8 Million
Q3 2017

Nov 02, 2017

BUY
$55.23 - $63.74 $12 Million - $13.8 Million
216,564
216,564 $13.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.